PDCD1 and lymphopenia: Boosting Th1-mediated inflammatory responses with PD-1 blockade, administrating steroids or anti-tumor necrosis factor-alpha agents to overcome immune-related adverse events and lymphopenia are among the potential mechanisms [25, 26].